Vilenchik M - Search Results

1

Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.

Ewton DZ, Hu J, Vilenchik M, Deng X, Luk KC, Polonskaia A, Hoffman AF, Zipf K, Boylan JF, Friedman EA. Ewton DZ, et al. Among authors: vilenchik m. Mol Cancer Ther. 2011 Nov;10(11):2104-14. doi: 10.1158/1535-7163.MCT-11-0498. Epub 2011 Aug 30. Mol Cancer Ther. 2011. PMID: 21878655 Free PMC article.

2

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.

Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, Roberts J, Cai J, Berkofsky-Fessler W, Hilton H, Linn M, Flohr A, Jakob-Røtne R, Jacobsen H, Glenn K, Heimbrook D, Boylan JF. Luistro L, et al. Among authors: vilenchik m. Cancer Res. 2009 Oct 1;69(19):7672-80. doi: 10.1158/0008-5472.CAN-09-1843. Epub 2009 Sep 22. Cancer Res. 2009. PMID: 19773430 Free PMC article.

3

Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.

Vilenchik M, Raffo AJ, Benimetskaya L, Shames D, Stein CA. Vilenchik M, et al. Cancer Res. 2002 Apr 1;62(7):2175-83. Cancer Res. 2002. PMID: 11929841

4

How to design potent and selective DYRK1B inhibitors? Molecular modeling study.

Szamborska-Gbur A, Rutkowska E, Dreas A, Frid M, Vilenchik M, Milik M, Brzózka K, Król M. Szamborska-Gbur A, et al. Among authors: vilenchik m. J Mol Model. 2019 Jan 23;25(2):41. doi: 10.1007/s00894-018-3921-3. J Mol Model. 2019. PMID: 30673861

5

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Vilenchik M, et al. Chem Biol. 2004 Jun;11(6):787-97. doi: 10.1016/j.chembiol.2004.04.008. Chem Biol. 2004. PMID: 15217612

6

Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides.

Benimetskaya L, Takle GB, Vilenchik M, Lebedeva I, Miller P, Stein CA. Benimetskaya L, et al. Among authors: vilenchik m. Nucleic Acids Res. 1998 Dec 1;26(23):5310-7. doi: 10.1093/nar/26.23.5310. Nucleic Acids Res. 1998. PMID: 9826753 Free PMC article.

7

Cellular delivery of antisense oligonucleotides.

Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M. Lebedeva I, et al. Among authors: vilenchik m. Eur J Pharm Biopharm. 2000 Jul;50(1):101-19. doi: 10.1016/s0939-6411(00)00088-6. Eur J Pharm Biopharm. 2000. PMID: 10840195 Free article. Review.

8

Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition.

Vilenchik M, Benimetsky L, Kolbanovsky A, Miller P, Stein CA. Vilenchik M, et al. Antisense Nucleic Acid Drug Dev. 2001 Apr;11(2):87-97. doi: 10.1089/108729001750171317. Antisense Nucleic Acid Drug Dev. 2001. PMID: 11334144

9

Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors.

Alexandrov V, Vilenchik M, Kantidze O, Tsutskiridze N, Kharchilava D, Lhewa P, Shishkin A, Gankin Y, Kirpich A. Alexandrov V, et al. Among authors: vilenchik m. J Med Chem. 2022 Oct 27;65(20):13784-13792. doi: 10.1021/acs.jmedchem.2c00988. Epub 2022 Oct 14. J Med Chem. 2022. PMID: 36239428 Free PMC article.

10

Hsp90: the vulnerable chaperone.

Chiosis G, Vilenchik M, Kim J, Solit D. Chiosis G, et al. Among authors: vilenchik m. Drug Discov Today. 2004 Oct 15;9(20):881-8. doi: 10.1016/S1359-6446(04)03245-3. Drug Discov Today. 2004. PMID: 15475321 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page